6-O-benzylguanine

Generic Name: 6-O-benzylguanine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₁N_₅O

CAS Number: 19916-73-5

Unique Ingredient Identifier: 01KC87F8FE

Background: 6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: O6-benzylguanine
Drug: carmustine

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00005961

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 10 locations

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Phase 1

Terminated

Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

Interventions: Drug: O6-benzylguanine
Drug: carmustine
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00003613

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma

Phase 3

Completed

Conditions: Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System

Interventions: Drug: carmustine
Radiation: radiation therapy
Drug: O6-Benzylguanine

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-30

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 183

Registration Number: NCT00017147

Locations: 🇺🇸
Freeman Cancer Institute at Freeman Health System, Joplin, Missouri, United States
🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸
Glacier Oncology, PLLC, Kalispell, Montana, United States

and more 160 locations

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT00005981

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Brain and Central Nervous System Tumors
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT00003567

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-20

Lead Sponsor: Duke University

Registration Number: NCT00006474

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT00004072

Locations: 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Phase 1

Terminated

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2009-10-16

Lead Sponsor: Pediatric Brain Tumor Consortium

Target Recruit Count: 3

Registration Number: NCT00045721

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 6 locations

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Extragonadal Germ Cell Tumor
Sarcoma
Kidney Cancer
Liver Cancer
Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020150

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy